BioMedomics has developed and launched one of the world’s first rapid point-of-care lateral flow immunoassays for the diagnosis of coronavirus infection. The test has been used widely by the Chinese CDC to combat infections and is now available globally. This test detects both early marker and late marker, IgM/IgG antibodies in human finger-prick or venous blood samples. It can also be used to test human serum or plasma samples.
This CE marked test can be used for rapid screening of carriers of the virus that are symptomatic or asymptomatic. Recent studies suggest that a high percentage of patients show no clinical symptoms of the virus, thus screening patients is vitally important. The test is ideally suited for hospitals, clinics and test laboratories. The test can also be effectively deployed in businesses, schools, airports, seaports and train stations, etc., giving it the potential to become a compelling force in the fight against this global threat.
Detection of IgM and IgG antibodies to COVID-19 in a single test
Suitable for whole blood, serum and plasma samples
Results in 15 minutes
Validated using PCR
No special facilities or equipment necessary
No specialised training required
Room temperature storage
How it works
To obtain more accurate results, this test is best carried out 21 days post symptoms.
Collect blood / serum / plasma sample
Add blood / serum / plasma sample to sample well
Place 2-3 drops of buffer in sample well
Read results by eye after 15 minutes
As stated above, obtain more accurate results, this test is best carried out 21 days post symptoms.